{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '11.1.2.', 'Baseline Assessments', '47', '11.1.2.1.', 'Medical History and Physical Examinations', '47', '11.1.3.', 'Vital Signs', '47', '11.1.4.', 'Weight and Height', '48', '11.1.5.', 'Physical Examination', '48', '11.1.6.', 'Urine Pregnancy Testing', '48', '11.1.7.', 'Focused Ears, Nose and Throat (ENT) Examinations', '48', '11.1.8.', 'Confirmation of Medical Care by Another Physician', '50', '11.2.', 'Adverse and Serious Adverse Events', '50', '11.2.1.', 'Adverse Event', '50', '11.2.1.1.', 'Assessment of Severity of Adverse Events', '51', '11.2.1.2.', 'Serious Adverse Event', '51', '11.3.', 'Relationship to Study Drug', '53', '11.4.', 'Recording Adverse Events', '53', '11.4.1.', 'Collection of Adverse Events', '53', '11.4.2.', 'Recording of Adverse Events', '54', '11.5.', 'Reporting Adverse Events', '54', '11.5.1.', 'Pregnancy', '55', '12.', 'TIMING OF STUDY ASSESSMENTS', '56', '12.1.', 'Screening Visit: Visit 1 (Day - -7 to - 10)', '56', '12.2.', 'Randomization Visit: Visit 2 (Day 1)', '57', '12.3.', 'Treatment Visit: Visit 3 (Day 8=2)', '58', '12.4.', 'Final Visit/Early Discontinuation Visit: Visit 4 (Day 15+2)', '59', '12.5.', 'Discontinuation Visit', '59', '12.6.', 'Unscheduled Visit', '60', '12.7.', 'Follow-Up Visit', '60', '13.', 'STATISTICS', '60', '13.1.', 'Sample Size', '60', '13.2.', 'Analysis Sets', '60', '13.2.1.', 'Full Analysis Set', '61', '13.2.1.1.', 'Per Protocol Set', '61', '13.2.1.2.', 'Safety Analysis Set', '61', '13.3.', 'Endpoints', '61', 'Glenmark', 'CONFIDENTIAL', 'Page 13 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '13.3.1.', 'Primary Endpoint', '61', '13.3.2.', 'Secondary Endpoints', '61', '13.3.3.', 'Other Endpoints', '61', '13.4.', 'Safety Endpoints', '62', '13.5.', 'Subject Disposition', '63', '13.6.', 'Demographic and Other Baseline Characteristics', '63', '13.7.', 'Efficacy Analyses', '63', '13.7.1.', 'Analysis of the Primary Efficacy Endpoint', '63', '13.7.2.', 'Analysis of Secondary Efficacy Endpoints', '63', '13.7.3.', 'Hierarchical Testing', '64', '13.8.', 'Safety Analyses', '64', '13.8.1.', 'Extent of Exposure', '64', '13.8.2.', 'Adverse Events', '64', '13.8.3.', 'Adverse Events, Concomitant Medications, and Withdrawals', '65', '13.8.4.', 'Vital Signs', '65', '13.8.5.', 'Physical Examinations', '65', '13.8.6.', 'Focused Ears, Nose, and Throat (ENT)/Eye Examinations', '65', '13.9.', 'Interim Analysis', '65', '14.', 'DIRECT ACCESS TO SOURCE DATA/DOCUMENTS', '66', '14.1.', 'Study Monitoring', '66', '14.2.', 'Audits and Inspections', '66', '14.2.1.', 'Inspection', '66', '14.2.2.', 'Audit', '67', '14.3.', 'Institutional Review Board/Independent Ethics Committee', '67', '15.', 'QUALITY CONTROL AND QUALITY ASSURANCE', '67', '16.', 'ETHICS', '67', '16.1.', 'Ethics Review', '67', '16.2.', 'Ethical Conduct of the Study', '68', '16.3.', 'Written Informed Consent', '68', '16.4.', 'Approval of the Protocol and Amendments', '69', '16.5.', 'Protocol Deviation', '69', '17.', 'DATA HANDLING AND RECORDKEEPING', '69', '17.1.', 'Data Collection', '69', 'Glenmark', 'CONFIDENTIAL', 'Page 14 of 90']\n\n###\n\n", "completion": "END"}